14th week of 2012 patent applcation highlights part 31 |
Patent application number | Title | Published |
20120082642 | Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors - A method for treating adult onset neurodegenerative diseases and diabetes by administering an effective dose of Granulocyte-Colony Stimulating Factors. | 2012-04-05 |
20120082643 | Compositions and Methods for Modulating a Cytotoxic T Lymphocyte Immune Response - The present invention provides compositions and methods for the treatment and prevention of immune disorders. | 2012-04-05 |
20120082644 | CYTOKINES AND NEUROANTIGENS FOR TREATMENT OF IMMUNE DISORDERS - The present invention provides methods of regulating an immunological disorder comprising administering to a subject an effective amount of (i) an autoimmune antigen in conjunction with (ii) an anti-inflammatory cytokine. Compositions including the same are also provided. | 2012-04-05 |
20120082645 | 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF - The present disclosure provides 2′-C-methyl-ribofuranosyl cytidine prodrugs, methods of making 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions of 2′-C-methyl-ribofuranosyl cytidine prodrugs, and methods of using 2′-C-methyl-ribofuranosyl cytidine prodrugs and pharmaceutical compositions thereof to treat viral diseases such as hepatitis C. | 2012-04-05 |
20120082646 | Antiviral Compounds And Uses Thereof - This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. | 2012-04-05 |
20120082647 | INTERFERON-BETA FOR USE AS MONOTHERAPY OR IN COMBINATION WITH OTHER CANCER THERAPIES - This description relates to the use of a polymer-conjugated interferon-beta as monotherapy or in combination with other cancer therapies. | 2012-04-05 |
20120082648 | Colonization factor (CF) antigens of enterotoxigenic escherichia coli in recombinant bacteria - strains, such as enterotoxigenic | 2012-04-05 |
20120082649 | PERIVASCULAR MESENCHYMAL PRECURSOR CELLS - Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as MUC 18, VCAM-1 and STRO-1 | 2012-04-05 |
20120082650 | METHODS FOR TREATING PARKINSON'S DISEASE AND OTHER DISORDERS OF DOPAMINERGIC NEURONS OF THE BRAIN - A specific clinical protocol for use toward therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Parkinson's disease. The protocol is practiced by directly delivering a definite concentration of a nerve growth factor via delivery of the protein, an expression vector operably encoding the nerve growth factor, or grafting a donor cell containing such an expression vector into the substantia nigra and preferably also the striatum. The method stimulates growth of targeted neurons, and reversal of functional deficits associated with the neurodegenerative disease being treated. | 2012-04-05 |
20120082651 | BACTERIA THYA(-) MUTANTS WITH INCREASED VITAMIN K - Bacteria thyA(−) mutants with increased vitamin K and use of these thyA(−) mutants for making a composition/product for treatment and/or prevention of vitamin K deficiency in a mammal (e.g. a human). | 2012-04-05 |
20120082652 | METHODS AND DEVICES FOR COLLECTING SEPARATE COMPONENTS OF WHOLE BLOOD - A method provides for procuring platelet rich plasma (PRP) from a sample of whole blood in a vial. The method includes the steps of: separating the whole blood into layers through centrifugation with an upper layer containing platelet poor plasma (PPP) and a PRP layer below the upper layer containing PRP; adjusting an end point of a first range of motion of an extractor relative to a position of the PRP layer; moving the extractor through the first range of motion through the vial, PPP passing out from the upper layer through the extractor; and after the extractor reaches the end point of the first range of motion, extracting the PRP through the extractor and collecting the PRP. | 2012-04-05 |
20120082653 | METHODS OF LYSOSOMAL STORAGE DISEASE THERAPY - Methods of treating a lysosomal storage disorder and methods of increasing cellular uptake of a lysosomal enzyme using β2 agonists or therapeutic agents that increase expression of receptors for a lysosomal enzyme. | 2012-04-05 |
20120082654 | Method For Preventing And Controlling Organisms That Infest Aqueous Systems - Method for preventing and controlling organisms that infest aqueous systems in which one or more organic or inorganic compounds capable of releasing gas are present, comprising the step of dispersing on and/or in the aqueous mass a preparation comprising enzymes adapted to catalyze a reaction of the one or more compounds that leads to the formation of gas. | 2012-04-05 |
20120082655 | Downregulation of SPY1 by p53 as an essential component of p53-mediated effects - The present invention relates to a novel method of treating or preventing cancer as well as a novel method for diagnosing or monitoring cancer, wherein the cancer is caused by delayed entry to cellular senescence. More particularly, the present invention relates to a novel method of treating or preventing cancer, comprising a step of administering an agent selected to degrade, inhibit or downregulate Spy1 in a cell. The present invention also relates to a novel method of diagnosing or monitoring cancer, comprising the steps of treating a cell with UV radiation and measuring amounts of a Spy1 protein and a p53 protein, or a ratio thereof. | 2012-04-05 |
20120082656 | COMPOSITION COMPRISING THE PURIFIED EXTRACT OF BEE VENOM FOR PREVENTING AND TREATING DEGENERATIVE BRAIN DISEASE - The present invention relates to a composition comprising the purified extract of bee venom for preventing and treating degenerative brain diseases and the use thereby. The purified extract of bee venom shows potent inhibitory effect on microglial cell activation and abnormal circling behavior using by animal model of degenerative brain disease as well as potent cell-protective activity therefore, it can be useful in treating and preventing the degenerative brain disease as a medicament. | 2012-04-05 |
20120082657 | SKIN PREPARATION CONTAINING FERMENTED SOYBEAN PASTE - The present invention relates to a skin preparation containing fermented soybean paste, which has been traditionally called as ‘Chungkookjang’ in Korea. Further, the skin preparation of present invention has a useful effect for preventing or treating the atopic dermatitis by the active ingredients contained in Chungkookjang. Further, the skin preparation consists of soap and lotion containing fermented soybean paste, wherein i) said soap contains the high molecular weight materials or water insoluble materials in fermented soybean paste, such as, edible fiber, polysaccharide, proteins, lipids and/or water insoluble health functional materials; and ii) said lotion contains the low molecular weight materials or water soluble ions in fermented soybean paste, such as, low molecular weight of sugar, oligo-saccharide, amino acid, peptide and/or water soluble health functional materials | 2012-04-05 |
20120082658 | Methods for the Treatment of Allergic Diseases - The present invention is directed generally to a TLR8 agonist VTX-378, for use in the treatment or prevention of allergic diseases, including allergic rhinitis. | 2012-04-05 |
20120082659 | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations - Disclosed are compositions and methods related to new targets for cancer treatment. | 2012-04-05 |
20120082660 | ANTI-TNF INDUCED APOPTOSIS (ATIA) DIAGNOSTIC MARKERS AND THERAPIES - The invention features diagnostic and therapeutic methods and compositions featuring Anti-TNF Induced Apoptosis (ATIA). ATIA is useful as a diagnostic marker for cancer, in particular for glioblastoma. ATIA is also a therapeutic target in diseases such as cancer. The invention encompasses combination therapies where knockdown of ATIA is used in combination with other treatment. The invention also features kits for use in the diagnostic and therapeutic methods. | 2012-04-05 |
20120082661 | ANTI-BCMA ANTIBODIES - This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases. | 2012-04-05 |
20120082662 | ANTI-CMET ANTAGONISTS - The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies. | 2012-04-05 |
20120082663 | ANTI-CMET ANTAGONISTS - The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies. | 2012-04-05 |
20120082664 | OPTIMIZED ANTIBODIES THAT TARGET CD19 - The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention. | 2012-04-05 |
20120082665 | PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO SPHINGOSINE-1-PHOSPHATE - The present invention relates to use of anti-S1P agents, for example, humanized monoclonal antibodies, for prevention and/or treatment of pain, including neuropathic pain, hyperalgesia, allodynia, and chemotherapy-induced pain. | 2012-04-05 |
20120082666 | ANTIBODY COMPOSITIONS AND METHODS OF USE - The invention provides compositions comprising anti-gH antibodies and anti-Complex I antibodies as well as methods of using the same. | 2012-04-05 |
20120082667 | Antibodies That Specifically Bind To A Beta Oligomers And Use Thereof - The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease. | 2012-04-05 |
20120082668 | SOLUBLE IL-17RA/RC FUSION PROTEINS AND RELATED METHODS - Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F. | 2012-04-05 |
20120082669 | HUMAN EPO MIMETIC HINGE CORE MIMETIBODIES, COMPOSITIONS, METHODS AND USES FOR PREVENTING OR TREATING GLUCOSE INTOLERANCE RELATED CONDITIONS OR RENAL DISEASE ASSOCIATED ANEMIA - The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, and methods of making and using thereof, for preventing or treating glucose intolerance and/or renal disease associated anemia, including therapeutic compositions, methods and devices. | 2012-04-05 |
20120082670 | CD33 BINDING AGENTS - The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS). | 2012-04-05 |
20120082671 | MODULATION OF ACTIVITY OF NEUROTROPHINS - The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. | 2012-04-05 |
20120082672 | Botulinum Neurotoxin B Receptors and Use Thereof - It is disclosed here that synaptotagmin I (syt I) and synaptotagmin II (syt II) are the cellular receptors for botulinum neurotoxin B (BoNT/B) that mediate the cellular entry and toxicity of BoNT/B. The BoNT/B binding domains of syt I and II are also disclosed. While syt I needs gangliosides for BoNT/B binding, syt II can bind to BoNT/B in the absence of gangliosides. Various nucleic acids and polypeptides that relate to the BoNT/B binding domain of syt I or II are disclosed. Further disclosed are methods of reducing BoNT/B toxicity, methods of identifying agents that can block the binding between BoNT/B and syt I or II, methods of identifying agents that can bind to the BoNT/B binding domain of syt I or II, methods of detecting BoNT/B or | 2012-04-05 |
20120082673 | HUMAN CYTOKINE RECEPTOR - Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.” | 2012-04-05 |
20120082674 | ENTEROCOCCUS ANTIGENS - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 2012-04-05 |
20120082675 | INSULIN-LIKE GROWTH FACTOR SIGNALING AND INTEGRIN - Interaction between insulin-like growth factor 1 (IGFI) and integrin is involved in integrin-mediated cellular signaling, such as enhanced proliferation of cells expressing integrins, especially integrin alpha v beta 3, alpha 6 beta. 1 and alpha 6. beta. 4. A method for inhibiting integrin signaling by using an inhibitor of IGFI-integrin binding is disclosed A method for identifying inhibitors of IGFI-integrin binding is also described. Further disclosed are polypeptides, nucleic acids, and corresponding compositions for inhibiting integrin signaling. | 2012-04-05 |
20120082676 | METHODS FOR PREVENTING AND TREATING ANGIOEDEMA - One aspect of the present invention provides a method of treating or preventing angioedema in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R. One aspect of the present invention provides a method of treating or preventing vascular permeability in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R. | 2012-04-05 |
20120082677 | COMPOSITIONS FOR THE TREATMENT OF HCV AND HBV - Therapeutic compositions for the treatment of viral hepatitis B (HBV) and hepatitis C (HCV) comprise antistreptokinase and antistreptolysine antibodies and/or tranexamic acid. Three antibodies against: polymerase, plasmin activators and fibrin are found in the blood of hepatitis C infected patients. | 2012-04-05 |
20120082678 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 2012-04-05 |
20120082679 | ANTAGONISTS OF PCSK9 - Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure. | 2012-04-05 |
20120082680 | ANTAGONISTS OF PCSK9 - Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure. | 2012-04-05 |
20120082681 | ANTI-IL12RBETA1 ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS - The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFNγ production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders. | 2012-04-05 |
20120082682 | IL-13 BINDING PROTEIN - The present invention relates to antigen binding proteins to human IL-13, including anti-IL-13 antibodies and anti-IL-3/anti-IL-4 mAbdAbs, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as asthma or IPF. | 2012-04-05 |
20120082683 | Superagonistic Anti-CD28 Antibodies - The present invention relates to one or more nucleic acid(s) encoding a binding molecule specifically binding to a human CD28 molecule, comprising
| 2012-04-05 |
20120082684 | DIAGNOSIS AND TREATMENT OF CELL PROLIFERATION AND DIFFERENTIATION DISORDERS BASED ON THE FMN2 GENE - The present invention provides methods for diagnosing cell proliferation and/or differentiation disorders, compounds and methods for treating the same and methods for identifying agents potentially useful in the treatment of cell proliferation and/or differentiation disorders. | 2012-04-05 |
20120082685 | Dock-and-Lock (DNL) Constructs for Human Immunodeficiency Virus (HIV) Therapy - The present invention concerns methods and compositions for treatment of HIV infection in a subject, utilizing a DNL complex comprising at least one anti-HIV therapeutic agent, attached to an antibody, antibody fragment or PEG. In a preferred embodiment, the antibody or fragment binds to an antigen selected from gp120, gp41, CD4 and CCR5. In a more preferred embodiment the antibody is P4/D10 or 2G12, although other anti-HIV antibodies are known and may be utilized. In a most preferred embodiment, the anti-HIV therapeutic agent is a fusion inhibitor, such as T20, T61, T651, T1249, T2635, CP32M or T-1444, although other anti-HIV therapeutic agents are known and may be utilized. The DNL complex may be administered alone or may be co-administered with one or more additional anti-HIV therapeutic agents. | 2012-04-05 |
20120082686 | Neovascular-Targeted Immunoconjugates - Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344. | 2012-04-05 |
20120082687 | Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use - Disclosed is a method to recover an antigen presenting cells (APCs) and immune cells rich mixture (AIM) from peripheral blood mononuclear cells (PBMC) mobilized with one or more cell adhesion inhibitors for the preparation of an AIM vaccine or an AIM adoptive immunotherapy preparation. In addition, AIM mobilization can be enhanced by priming, simultaneously or in sequence, one or more of a combination of different chemical compounds, cytokines, hormones, growth factors, etc. The interaction of chemokines and chemokine receptors enable tumor cells attachment or in close proximity to antigen presenting cells and immune cells which possess similar receptors in a micro niche environment. Severing the chemokine/chemokine receptor linkage by a cell adhesion inhibitor will release these specifically primed cell mixtures into the peripheral blood. The collection of these cells from the peripheral blood has never been described and is the basis of this invention. AIM cells can either be used alone or better still, be induced into more target specific preparations with additions, modifications and incubation, pre or post cell adhesion inhibitors mobilization, with vaccines, different target specific antigens, peptides, chemotherapeutic agents, oncolytic viral therapeutic agents, cytokines, co-stimulatory molecules, anti-regulatory T cell therapeutic agents, anti-CTLA4, anti-PD1 molecules and other methodologies of immunological enhancement known to the art. The AIM vaccine or AIM adoptive immunotherapy preparation can then be used, but not limited to, the treatment of cancer and other diseases. | 2012-04-05 |
20120082688 | In Vitro Generation of Myeloid Derived Suppressor Cells - The invention relates to methods of isolating, culturing, and differentiating myeloid derived suppressor cells (MD-SCs) from embryonic stem (ES) cells and hematopoietic stem cells (HSCs). In certain embodiments, the invention relates to methods and compositions for producing MDSCs from ES cells and HSCs using a combination of factors including macrophage colony-stimulating factor (M-CSF). | 2012-04-05 |
20120082689 | Method of treatment an oncological disease - Method of cancer treatment with direct contact between proteins secreted by cancer tumor and patient's blood T-lymphocytes including the stage of weakening during some time humoral system of immunity by medical preparation, in particular by immunodepressant against this system, without weakening cellular system of immunity. | 2012-04-05 |
20120082690 | CHAPERONIN 10 IMMUNOSUPPRESSION - The invention is directed to the use of cpn10 in transplantation and particularly to treatment and/or prevention of graft versus host disease. The invention provides a method of administration of cpn10 to a donor and/or recipient animal or cells, tissues or organs derived from the donor, although in a particularly advantageous form treatment of both the donor and recipient animal. The method may further include the administration to the donor and/or recipient animal at least one other immunosuppressive agent to prevent or alleviate graft versus host disease. | 2012-04-05 |
20120082691 | HLA-BINDING PEPTIDES DERIVED FROM PROSTATE-ASSOCIATED ANTIGENIC MOLECULES AND METHODS OF USE THEREOF - Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. Patients are treated with compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants. | 2012-04-05 |
20120082692 | Identification, Optimization and Use of Cryptic HLA-A24 Epitopes for Immunotherapy - The present invention pertains to methods for identifying a HLA-A*2402-restricted cryptic epitope in an antigen, and for increasing its immunogenicity, in order to obtain HLA-A*2402-restricted epitopes able to trigger an immune response against HLA-A*2402-restricted cryptic epitopes. Isolated peptides consisting of cryptic or optimized HLA-A*2402-restricted epitopes are provided. | 2012-04-05 |
20120082693 | USE OF PROTEINS AND PEPTIDES ENCODED BY THE GENOME OF A NOVEL SARS-ASSOCIATED CORONAVIRUS STRAIN - The invention relates to the use of proteins and peptides coded by the genome of the isolated or purified strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from sample reference number 031589 and, in particular, to the use of protein S and the derivative antibodies thereof as diagnostic reagents and as a vaccine. | 2012-04-05 |
20120082694 | Recombinant Viral-Based Malaria Vaccines - Described are vaccines against malarial infections, which are based on recombinant viral vectors, such as alpha viruses, adenoviruses, or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different | 2012-04-05 |
20120082695 | COSMETIC ACTIVE PREPARATION - A cosmetic formulation comprises extracts and/or their derivatives, i.e., sea aster, brown algae, coral algae and Irish moss. In addition, metal-bound peptides are also contained in the cosmetic formulation. These components of the cosmetic formulation reinforce each other mutually so that the entire formulation exhibits favorable moisturizing effects that soothe the skin and increase its elasticity. Furthermore, a skin treated with it is very largely protected from damaging external environmental influences. | 2012-04-05 |
20120082696 | INTERGENIC REGIONS AS INSERTION SITES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA (MVA) - The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine. | 2012-04-05 |
20120082697 | METHOD FOR PROPHYLAXIS OF INFLUENZA USING VACCINE FOR INTRANASAL ADMINISTRATION - The present invention provides a vaccine composition for transnasal mucous membrane administration, which contains an influenza virus antigen, polyriboinosinic polyribocytidylic acid (poly (I:C)) or a derivative thereof and a carboxyvinyl polymer. The present invention also provides a prophylactic method of influenza, including a step of administering the vaccine composition at least once to the nasal mucosa of a subject in need thereof. | 2012-04-05 |
20120082698 | MUTANTS OF FRANCISELLA TULARENSIS AND USES THEREOF - The present invention relates to a mutant | 2012-04-05 |
20120082699 | Method of Producing Rough Strains of Bacteria and Uses Thereof - The present invention relates to a method of producing rough strains of a bacterium, such as | 2012-04-05 |
20120082700 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS - Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a TLR9 agonist and a TLR 2/6 agonist to the individual. | 2012-04-05 |
20120082701 | POLARIZED SCORPION VENOM SOLUTION AND A METHOD FOR MAKING POLARIZED SCORPION VENOM SOLUTION - The present invention discloses a polarized dilute blue scorpion venom solution and a method for administering dilute scorpion venom solution. The polarized dilute scorpion venom solution provides treatment to various diseases and conditions such as relieving pain, improving immune-system responses, treating cancer, preventing cancer, improving quality of sleep, reducing inflammation, and minimizing negative biological response to chemotherapy and radiation treatment | 2012-04-05 |
20120082702 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS - Disclosed are nicotinamide compounds of Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds in the treatment of at least one Btk associated condition, such as, for example, inflammatory disease, and pharmaceutical compositions comprising such compounds. | 2012-04-05 |
20120082703 | PHARMACEUTICAL COMPOSITION AND USE OF THE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT, PROPHYLAXIS OR PREVENTION OF NEOPLASTIC DISEASES IN HUMANS AND ANIMALS - The present invention relates to pharmaceutical compositions comprising polyfunctional metal phenolates that have biological applications as an anticancer adjuvant, cytoprotective antimetastatic agents and antimutagenic agents when associated with chemotherapy drugs. | 2012-04-05 |
20120082704 | Oxygenated demineralized bone matrix for use in bone growth - An improved composition for inducing bone growth is provided that is a combination of at least DBM and an oxygen carrier. Injection/implantation of a composition of DBM and an oxygen carrier (e.g. a perfluorocarbon) results in enhancement of bone formation compared to DBM alone. | 2012-04-05 |
20120082705 | Tetra Calcium Phosphate Based Organophosphorus Compositions and Methods - Compositions and methods of their use to adhere a variety of materials together are disclosed herein. The compositions include at least tetra calcium phosphate, an effective amount of a compound that is structurally similar to phosphoserine, and can be mixed with an aqueous solution. The compositions provide adhesive and cohesive strength in both wet and dry environments and exhibit significant bond strength upon curing. | 2012-04-05 |
20120082706 | MEDICAL DEVICE FOR DRUG DELIVERY - A medical device for safe and sure delivery of drugs to the lesion and a method for production thereof. The medical device has at least part of its surface in contact with the lumen wall tissue of the living body coated with a drug releasing layer containing a drug and a phospholipid, the drug and the phospholipid forming a solid dispersion. | 2012-04-05 |
20120082707 | ANTIPERSPIRANT PRODUCTS HAVING ANTIBACTERIAL PROTECTION AND PROCESSES FOR MAKING THE SAME - A personal care product comprises an antiperspirant product that comprises an active antiperspirant compound, and titanium dioxide particles that comprise anhydrous silver compound selected from the group consisting of anhydrous silver chloride, anhydrous silver lactate, anhydrous silver citrate, and mixtures thereof. | 2012-04-05 |
20120082708 | NOVEL METHOD FOR PREPARING COMPOSITE PARTICLE COMPRISING SURFACE TREATMENT LAYER OF SUNSCREENING AGENT FORMED THEREON - The present invention relates to a method of preparing a composite powder comprising a surface treatment layer of sunscreen. The present invention prepares a composite powder comprising a surface treatment layer of sunscreen by a dry process that does not require separate dehydration and drying processes, and thus, the prepared composite powder may be uniformly surface-treated with more quantities of sunscreens compared to a composite powder comprising a surface treatment layer of sunscreen prepared by a conventional wet process, may exhibit remarkably improved sun screen effect, and be useful for a cosmetic composition. | 2012-04-05 |
20120082709 | COMPOSITIONS AND METHODS FOR DELIVERY OF MATERIALS - Compositions for delivering release materials, for example drugs, agricultural materials, other bioactive materials, cosmetic materials, organic or inorganic compounds which take part in or catalyse a chemical reaction, a fragrance-emitting material for a vaporizer, or a lubricating material. The release material is associated with a crystalline carrier. The carrier may be a crystalline polymer containing a plurality of crystalline groups or a crystalline monomer which contains a single crystalline group, the crystalline group preferably comprising a straight chain polymethylene radical containing at least 16 carbon atoms. Some of the carriers are obtained by modifying hyaluronic acid, collagen, gelatin, a polysaccharide, a carbohydrate or cyclodextran. The release material may contain a similar crystalline group, for example may be an active compound which has been modified to introduce a crystalline group. | 2012-04-05 |
20120082710 | METHODS AND COMPOSITIONS FOR TREATING ACNE - A method for treating acne on the skin. The method has the steps of (a) providing an drapeable or flexible porous article impregnated with an aqueous cleansing composition having a carrier, benzoyl peroxide, and one or more cleansing agents; (b) contacting an area of the skin affected by acne with the porous article such that the skin is contacted by the composition; and (c) removing the composition from the skin wherein residual benzoyl peroxide remains on the skin in an anti-acne effective amount. There are also anti-acne compositions. | 2012-04-05 |
20120082711 | ANTIMICROBIAL COMPOSITIONS AND FIBRES INCORPORATING THE SAME - The present application defines an antimicrobial composition comprising (a) at least two antimicrobial agents having different antimicrobial mechanisms of action and being present in amounts that together provide a synergistic antimicrobial effect or (b) an antimicrobial agent and a surface modifying agent, an antimicrobial masterbatch comprising antimicrobial composition (a) or (b) and a polymer carrier, an antimicrobial fibre composition comprising the antimicrobial masterbatch and a fibre substrate, an antimicrobial fibre comprising a fibre body or a fibre surface having the antimicrobial fibre composition, and a process for producing antimicrobial fibres. | 2012-04-05 |
20120082712 | Implantable Polymeric Films - The present disclosure relates to implantable medical devices containing a polymeric film layer containing glycerol and at least one biopolymer. | 2012-04-05 |
20120082713 | PHOTOCHROME- OR NEAR IR DYE-COUPLED POLYMERIC MATRICES FOR MEDICAL ARTICLES - The invention provides polymers comprising pendent photochrome or near IR dye groups, as well as polymeric matrices made from these polymers, which can be used as or in association with a medical article. The polymers can be synthesized using methods that facilitate the preparation of medical articles having good biocompatibility. Exemplary polymeric matrices are in the form of lubricious coatings on medical devices, such as catheters. Visualization by irradiation of the photochrome or near IR dye can improve detection of the polymeric matrix on a device or in the body. This, in turn can improve aspects of a medical procedure, such as device insertion or matrix formation, as well as being useful for assessing the quality of the matrix. | 2012-04-05 |
20120082714 | TRANSDERMAL THERAPEUTIC SYSTEM WITH CRYSTALLIZATION-INHIBITING PROTECTIVE FILM (RELEASE LINER) - The invention relates to pharmaceutical formulations, in particular to transdermal therapeutic systems, which are characterized in that little or no active ingredient crystallizes out at the interface between the removable protective film (release liner) and the active-ingredient-containing matrix. | 2012-04-05 |
20120082715 | Stabilized products, processes and devices for preparing the same - A composition comprising a glassified, stabilized particle preparation having a low water activity (between about 0.1 and 0.9) is provided. The preparations provide improved products with enhanced storage stability, less expensive cost of processing, and extended shelf life. The glassified, stabilized particle preparations are particularly efficacious in the preparation of perishable products, especially pharmaceutical agents, such as human blood and blood products (e.g., red blood cells). A single emulsion process comprising a 2-phase system for preserving food and pharmaceutical products is also provided. Stabilized biological products as glassified beads are also provided, as well as a method for rehydrating and/or reconstituting the glassified beads to provide useful and fully active reconstituted and/or rehydrated materials is also presented. | 2012-04-05 |
20120082716 | Cytotoxic agents - A method of killing a cell that is lacking in effective p53 protein activity, particularly as compared to wild type, is provided characterised in that it comprises delivering to the cell a single stranded DNA including a portion with at least one base, internally located with respect to any 3′ and 5′ ends of the DNA, that is unbasepaired with another base in a form that is capable of being internalised by the cell. | 2012-04-05 |
20120082717 | COMPLEX, MULTILAYER USING THE SAME, AND DEVICE COATED WITH THE MULTILAYER - Disclosed herein is a complex, wherein micelles and/or liposomes dispersed in hyaluronic acids and/or hyaluronic acid derivatives, with a drug and/or functional material loaded in the micelles and/or the liposomes. The complex can release the drug and/or functional material in a controlled manner. Also, a multilayer using the complex, and a device coated with the multilayer are disclosed herein. | 2012-04-05 |
20120082718 | Morphine Formulations - Described is a pellet composition comprising a core element comprising morphine sulfate, a filler and a binder, wherein the morphine sulfate, calculated as the anhydrous form, comprises about 50 wt % to about 85 wt % of the total weight of the core element; and a coating disposed on at least a portion of the core element, the coating comprising an insoluble matrix polymer which is insoluble at pH 1 to 7.5; an enteric polymer which is insoluble at pH 1 to 4 and soluble at pH 6 to 7.5; and an acid soluble polymer which is soluble at a pH of 1 to 4, wherein the ratio of the acid soluble polymer to the enteric polymer is 1.45:1 to 2.5:1 on a weight basis. Also described are dosage forms comprising the disclosed pellets. | 2012-04-05 |
20120082719 | Compositions For Treating Chronic Viral Infections - The present invention describes dietary compositions and methods of using such compositions to treat chronic viral infections, including hepatitis B and hepatitis C infections. | 2012-04-05 |
20120082720 | Compositions For Treating Chronic Viral Infections - The present invention describes dietary compositions and methods of using such compositions to treat chronic viral infections, including hepatitis B and hepatitis C infections. | 2012-04-05 |
20120082721 | Enteric coating - The present invention refers to a dosage form comprising an enteric coating in a specific amount, and to the use of enteric coating compositions for preparing a dosage form. Furthermore, the present invention also relates to a process for the preparation of a solid oral dosage form. | 2012-04-05 |
20120082722 | METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS - Disclosed are oral dosage forms containing a Ras antagonist including FTS and structural analogs thereof, and at least one pharmaceutically acceptable excipient other than a cyclodextrin, and methods of orally administering same to treat diseases and disorders responsive to the Ras antagonists. | 2012-04-05 |
20120082723 | Easily administrable solid preparation - It is an object to provide a coating composition, which is used for an orally-administered preparation, the administering property of which has been improved, and/or an easily administrable preparation that does not affect dissolution property. The aforementioned object can be achieved using a coating composition comprising a first thickener selected from the group consisting of a carboxyvinyl polymer and sodium alginate, a polyvalent metal compound, and at least one type of a second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate, with the proviso that when the first thickener is sodium alginate the second thickener is not sodium alginate, or using a coating composition comprising, as thickeners, hydroxypropylmethylcellulose and sugar or sugar alcohol having a solubility at 20° C. of 30 or more. | 2012-04-05 |
20120082724 | DRY MOULDABLE DRUG FORMULATION - Solid pharmaceutical compositions for parenteral injection comprising a binder and at least one therapeutic agent. The pharmaceutical composition has the strength to be injected directly with the need of using cannulas or the like. | 2012-04-05 |
20120082725 | Composition Comprising Immunogenic Microparticles - The invention provides an immunogenic composition comprising at least one antigen in association with microparticles, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting immune responses in a subject. | 2012-04-05 |
20120082726 | SURFACE-TREATED MODAFINIL PARTICLES - The present invention is directed to solid oral dosage forms comprising surface-treated particles comprising modafinil particles and a hydrophilic treating agent, methods of making the same, and uses thereof. | 2012-04-05 |
20120082727 | USE OF MAGNESIUM STEARATE IN DRY POWDER FORMULATIONS FOR INHALATION - Addition of magnesium stearate to a powder formulation for inhalation comprising carrier particles and an active ingredient bearing a group susceptible to hydrolysis is useful for inhibiting or reducing the chemical degradation of the active ingredient. | 2012-04-05 |
20120082728 | MULTIFUNCTIONAL STEALTH NANOPARTICULES FOR BIOMEDICAL USE - The present invention relates to the field of drug delivery nanosystems. More precisely, the present invention concerns a copolymer with advantageous properties for the outer coating of various nanoparticles. Said copolymer comprises at least three types of monomers with stealthy, coupling and therapeutic properties respectively, as well as an optional fourth type of monomers with targeting properties. The present invention also relates to core-shell or hollow shell nanoparticles coated by an external layer of the copolymer according to the invention. Several types of core-shell nanoparticles are envisaged. The invention also concerns methods for preparing said nanoparticles, as well as pharmaceutical compositions or medicaments comprising them. | 2012-04-05 |
20120082729 | QUICK DISSOLVE COMPOSITIONS AND TABLETS BASED THEREON - The invention provides a composition useful for making oral dosage forms capable of dissolving in the mouth in less than 40 seconds without the need for a conventional super disintegrant and having a friability of less than 1%; wherein the composition includes liquiflash particles and an excipient mass. A preferred excipient mass according to the invention contains a directly compressible inorganic salt; a cellulose derivative or a combination of a directly compressible inorganic salt and a cellulose derivative. Preferably, the liquiflash particles and the excipient mass are combined in proportions such that the active ingredient remains substantially within the microspheres when the composition is compressed to obtain a dosage form having a hardness of 20 to 50 N. The compositions of the invention allow for the fabrication of oral dosages having improved hardness and friability. | 2012-04-05 |
20120082730 | NANOPARTICULATE IN-SITU GELS AS VITREOUS HUMOR SUBSTITUTES FOR OCULAR DISEASES - The present technology provides a nanoparticulate in-situ gelling vitreous substitute, which is a liquid at room temperature to aid easy administration, such as e.g. through a small needle incision, and forms a gel within the eye, which is hydrophilic in nature, similar to the natural vitreous. The vitreous substitute formulation may include a water-soluble natural or synthetic polymer and a gelling-agent which are blended together in the presence of a cross linker, to form a gel having the properties of the vitreous humor. The process of cross linking and gelation may occur in-situ. This can be achieved by dispensing to the eye, different components of the vitreous substitute in liquid state, along with the cross linking agent. | 2012-04-05 |
20120082731 | Method For Removing Residual Organic Solvent From Microparticles - Disclosed herein are methods comprising suspending microparticles in a surfactant/non-polar alkane solution to remove residual solvent that is present in the microparticle. | 2012-04-05 |
20120082732 | MEDICINE FOR TREATMENT OF A CARCINOMA - In a method for treating a carcinoma in a patient, a medicine is administered via the blood stream of the patient that appears, to the patient's immune system, that tissue of the carcinoma is an inflammation source. The medicine employs two active components that are coupled to each other in a form allowing administration of the two active components to the carcinoma via the blood stream of the patient. A first of the active components is at least one coupling molecule that specifically tethers to a target molecule formed by cancer tissue of the carcinoma. A second of the active ingredients is at least one signal molecule typical to inflammation, or at least one originating molecule encoding such a signal molecule, that induces the immune system of the body to attack the cancer cells. | 2012-04-05 |
20120082733 | METHODS FOR PROCESSING MICROSPHERES, MICROSPHERES PROCESSED THEREBY, AND USES THEREOF - The invention provides a manufacturing method for processing polymeric microspheres which are suspended in a liquid. The invention also provides polymeric microspheres produced by the method which can be used in medical settings as tissue fillers, tissue bulking agents, embolization agents, and/or as drug delivery agents. | 2012-04-05 |
20120082734 | HYDROGEN PRODUCTION DEVICE, HYDROGEN ADDITION DEVICE AND HYDROGEN-ADDITIVE ARTICLE - A hydrogen production device includes a reaction unit and a hydrogen collection unit. The reaction unit includes a first region, a second region and a barrier layer. The first region stores a solid-state reactant, the second region stores a liquid-state reactant, and the barrier layer separates the first region from the second region. When the barrier layer forms an opening, the solid-state reactant comes into contact and reacts with the liquid-state reactant to produce hydrogen gas. The hydrogen collection unit has at least one gas vent to lead the hydrogen gas to flow into a hydrogen acceptor via the gas vent. The hydrogen gas is allowed to flow through the hydrogen collection unit, and the liquid-state reactant is prevented from entering the hydrogen collection unit. | 2012-04-05 |
20120082735 | Allergic skin desease topical cream - Disclosed is a cream formulation containing calamine, an H1 antihistamine, and a corticosteroid for the reduction of inflammation, redness and itching associated with acute and chronic allergic skin disease. | 2012-04-05 |
20120082736 | Small-molecule TNF modulator to reduce the side effects of chemotherapy and radiotherapy - Cancer patients treated by chemotherapy and/or radiotherapy often suffer serious side effects. Currently, there is only one FDA approved and used as both a chemoprotector and a radioprotector, amifostine, which is associated with significant problems. Disclosed in the present invention are novel methods of using UTL-5g as both a chemoprotector and radioprotector for treating cancer patients in addition to other related methods. | 2012-04-05 |
20120082737 | Topical Skin Care Formulations Comprising Plant Extracts - Disclosed are compositions and corresponding methods of their use that include extracts from a | 2012-04-05 |
20120082738 | MUCOSAL FORMULATION - Provided, among other things, is a method of treating or ameliorating an indication of mucosal or adjacent tissue comprising periodically applying to mucosa at or adjacent to disease affected tissue a rinse comprising: an effective amount of appropriate composition of herbal bioactive comprising active(s) of one or more of | 2012-04-05 |
20120082739 | Compositions and Methods for Treatment and Management of Pain - Disclosed herein are compositions and methods for the treatment and management of pain in a subject, comprising topically or orally administering a therapeutically effective amount of a composition comprising herbal extracts and compound mixtures to a subject. The composition includes turmeric extract, | 2012-04-05 |
20120082740 | METHOD FOR INCREASING CONCENTRATION OF AVENANTHRAMIDES IN OATS - Methods for increasing the levels of avenanthramides in oats through false malting is disclosed. Oats are first subject to induction or enhancement of a secondary dormancy, and then malted for up to 5 days at an elevated temperature. The malted but not germinated oats are then dried and used as is, or further processed or milled to produce food, feed, nutraceutical or personal care products and ingredients. Methods are also provided for rendering non-dormant oats dormant and thus suitable for false malting. | 2012-04-05 |
20120082741 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF RED BLOOD CELL COAGULATION - A pharmaceutical composition for inhibiting mammalian red blood cell coagulation is disclosed. The composition comprises an effective amount of | 2012-04-05 |